Employer health costs expected to see sharpest increase in 20 years: Survey
Marsh said 59% of employers plan cost-cutting changes, as rising premiums and deductibles could push workers’ health costs higher.
- On Wednesday, Marsh, a professional services firm, released its 2026 National Survey of Employer-Sponsored Health Plans, projecting an 8.2% average rise in health benefit costs for 2027.
- Rising prices for hospital care, prescription drugs, and cancer treatments drive cost growth, alongside newer expenses from AI-based medical documentation and increased demand for GLP-1 medications.
- Surveying over 1,800 employers, Marsh found 59% plan cost-cutting changes in 2027, including raising deductibles or limiting coverage for spouses to manage expenses.
- Employees face higher out-of-pocket costs and premiums, prompting companies to pursue direct contracting with hospitals or switch to smaller pharmacy benefit managers for transparency.
- Representing the sharpest increase since 2003, 2027 will mark the fifth consecutive year of elevated health benefit growth, affecting about 160 million people under 65 relying on employer insurance.
11 Articles
11 Articles
Employers prepare for a double-digit surge in healthcare costs
U.S. employers are preparing for the sharpest increase in healthcare costs in more than two decades, The New York Times reports. According to a Marsh survey of 1,800 employers, healthcare costs per employee are expected to rise an average of 11% next year, while costs are projected to increase about 8% after employers make changes […]
Employer Health Costs, Workers' Premiums Rising in 2027
According to a survey released this week by Marsh, U.S. employers are bracing for another steep increase in healthcare costs, with spending per worker projected to rise 11% next year before companies change their benefit plans.
Employer health costs expected to see sharpest increase in 20 years: Survey
Employer health benefit costs are projected to rise by 8.2% in 2027, the largest increase since 2003, according to Mercer, due to provider consolidation and enhanced therapeutics.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
















